Reaction

Which drugs are most reported with Uterine cancer?

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 7,997 reports · 49 co-occurring drugs

As of the last recalculation, Uterine Cancer appears in 7,997 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is RANITIDINE (PRR 26.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranitidine	1,644	26.8	27.0
Ranitidine Hydrochloride	385	19.3	19.5
Raloxifene Hydrochloride	40	7.2	7.2
Conjugated Estrogens	79	3.6	3.6
Estrogens, Conjugated	79	3.5	3.5
Conjugated Estrogens And Medroxyprogesterone Acetate	31	3.4	3.4
Tolterodine Tartrate	11	3.2	3.2
Cladribine	9	2.4	2.4
Anastrozole	31	2.2	2.2
Medroxyprogesterone Acetate	42	2.2	2.2
Valsartan And Hydrochlorothiazide	11	2.1	2.1
Interferon Beta-1A	137	1.9	1.9
Progesterone	15	1.7	1.7
Trastuzumab	42	1.6	1.6
Risankizumab-Rzaa	50	1.6	1.6
Insulin Human	24	1.6	1.6
Brinzolamide	5	1.5	1.5
Estradiol	49	1.5	1.5
Fosaprepitant Dimeglumine	7	1.3	1.3
Golimumab	43	1.3	1.3
Naltrexone Hydrochloride And Bupropion Hydrochloride	4	1.2	1.2
Imatinib Mesylate	13	1.2	1.2
Ustekinumab	46	1.2	1.2
Siponimod	4	1.2	1.2
Liraglutide	22	1.2	1.2
Fingolimod Hcl	38	1.1	1.1
Paricalcitol	6	1.1	1.1
Guselkumab	15	1.1	1.1
Dimethyl Fumarate	49	1.0	1.0
Glatiramer Acetate	23	1.0	1.0
Olaparib	8	1.0	1.0
Exenatide	20	1.0	1.0
Alpelisib	3	0.9	0.9
Diroximel Fumarate	4	0.9	0.9
Pazopanib Hydrochloride	9	0.9	0.9
Natalizumab	58	0.8	0.8
Crizotinib	4	0.8	0.8
Etanercept	189	0.8	0.8
Dalfampridine	22	0.8	0.8
Peginterferon Beta-1A	4	0.8	0.8
Lenvatinib	10	0.8	0.8
Copper	13	0.8	0.8
Ixekizumab	11	0.8	0.8
Ranibizumab	7	0.7	0.7
Alirocumab	6	0.6	0.6
Levonorgestrel	47	0.6	0.6
Dulaglutide	18	0.5	0.5
Apremilast	28	0.5	0.5
Paliperidone Palmitate	6	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.